Clinical Trials
9 trialsNCT07005128 2026-06-04
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT06598306 2026-05-29
DeLLphi-308
Amgen
Phase 1 Recruiting
NCT06117774 2026-04-29
DeLLphi-306
Amgen
Phase 3 Active not recruiting
NCT06745323 2026-03-03
DeLLphi-309
Amgen
Phase 2 Active not recruiting
NCT07423585 2026-02-20
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT06211036 2025-12-17
DeLLphi-305
Amgen
Phase 3 Active not recruiting
NCT04885998 2025-09-29
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
Amgen
Phase 1 Completed
NCT06064500 2025-03-10
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Amgen
Approved for marketing